ArticleBMC medical imaging2026
The influence of fine-needle aspiration on dual-layer detector spectral CT parameters of papillary thyroid carcinoma: a propensity-match analysis.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDual-layer detector spectral computed tomography (DLCT) and fine-needle aspiration (FNA) are commonly used in papillary thyroid carcinoma (PTC). However, whether FNA affects DLCT quantitative parameters remains uncertain. This study aimed to investigate the effect of FNA on DLCT parameters in PTC and to determine the optimal timing for DLCT examination.
methodsThis retrospective study included 689 patients with PTC, who were categorized into pre-FNA (n = 222) and post-FNA (n = 467) groups according to the sequence of FNA and DLCT. Propensity score matching (PSM) was applied to balance confounding variables. Sensitivity analyses were performed using inverse probability of treatment weighting and multivariate regression. DLCT parameters, including virtual monoenergetic images (VMIs) at 40, 70, and 100 keV; spectral attenuation curve slope (λ
resultsCovariates were well balanced after PSM, with all standardized mean differences below 0.25. Sensitivity analyses confirmed consistent direction of effect estimates across methods. Two clinically relevant exploratory temporal landmarks were observed around 6 and 18 days. Within 6 days after FNA, significant differences were observed in AP VMIs (40, 70, 100 keV), λHU, IC, NIC, and VP VMI at 100 keV. Between 7 and 18 days, only VP-IC remained significantly altered. Beyond 18 days, no parameters differed from pre-FNA baselines.
conclusionsDLCT parameters showed a dynamic post-FNA temporal pattern, with early and later candidate recovery windows centered around approximately 6 and 18 days. From a clinical perspective, DLCT may be considered before FNA or after about 6 days, whereas a later interval around 18 days may be preferable when minimizing biopsy-related perturbation is particularly important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.